Congestive Heart Failure (CHF) Practice Test (Sample)

Study Guide

Everything you need from our exam experts!

Table of Contents

Copyright **1**

Table of Contents **2**

Introduction **3**

How to Use This Guide **4**

Questions **5**

Answers **8**

Explanations **10**

Next Steps **16**

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- **Practice answering questions under realistic conditions,**
- **Improve accuracy and speed,**
- **Review explanations to strengthen weak areas, and**
- **Approach the exam with greater confidence.**

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here’s how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don’t just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There’s no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. Which statement best describes pregnancy considerations in heart failure management?

A. ACE inhibitors/ARBs are teratogenic; alternatives include hydralazine and nitrates; careful monitoring

B. ACE inhibitors/ARBs are safe in pregnancy

C. Hydralazine and nitrates are teratogenic

D. No special considerations

2. In acute HF treatment, which statement about vasodilatory therapy is listed?

A. Hospitalization

B. IV diuresis

C. Nesiritide recombinant human BNP

D. Nitrates and vasodilation

3. What is the prognostic significance of LV remodeling measurements like LV dilation or LVESV?

A. EF is the only prognostic factor.

B. Greater LV dilation and higher LVESV are associated with worse prognosis; EF is also prognostic.

C. LV dilation signals better prognosis.

D. LVESV has no prognostic value.

4. Stage A risk factors for heart failure include all of the following except?

A. Prior congestive heart failure

B. Hypertension

C. Coronary artery disease

D. Diabetes mellitus

5. Which therapy provides both resynchronization and defibrillation capabilities?

A. Cardiac resynchronization therapy

B. Implantable cardioverter-defibrillator

C. Left ventricular assist device

D. Combined resynchronization therapy and defibrillator

6. Which statement correctly identifies HF type and EF range?

A. HFrEF: EF ≤40%

B. HFmrEF: EF ≥50%

C. HFpEF: EF 30-40%

D. HFimpEF: EF 60-70%

7. Which of the following is NOT listed as a risk factor for heart failure?

A. Coronary artery disease

B. Obesity

C. Hypertension

D. Diabetes

8. Which statement about SGLT2 inhibitors in heart failure is correct?

A. They are only used to treat diabetes with no cardiovascular benefit.

B. They only benefit HFrEF, not HFpEF.

C. They are contraindicated in HF due to hypotension risk.

D. They reduce hospitalization for heart failure and cardiovascular death across HFrEF and HFpEF.

9. Why is BNP level interpretation age-dependent and what is a typical threshold for ruling out HF in non-elderly patients?

A. BNP thresholds are fixed and do not vary with age.

B. NT-proBNP thresholds vary with age; in younger patients a BNP <100 pg/mL or NT-proBNP <300 pg/mL helps rule out HF.

C. A BNP value below 200 pg/mL rules out HF in every patient.

D. BNP is not useful for ruling out HF in younger patients.

10. Which medication class is identified as warranting potassium monitoring when added to RAAS inhibitors in heart failure?

A. Potassium-sparing diuretics

B. Beta-blockers

C. ACE inhibitors

D. Calcium channel blockers

Answers

1. A
2. D
3. A
4. A
5. D
6. A
7. B
8. D
9. B
10. A

Explanations

1. Which statement best describes pregnancy considerations in heart failure management?

A. ACE inhibitors/ARBs are teratogenic; alternatives include hydralazine and nitrates; careful monitoring

B. ACE inhibitors/ARBs are safe in pregnancy

C. Hydralazine and nitrates are teratogenic

D. No special considerations

In pregnancy, heart failure treatment must protect both mother and fetus, so certain medicines are avoided because of fetal risks. ACE inhibitors and ARBs disrupt fetal kidney development and can cause renal injury, oligohydramnios, and other serious fetal problems, especially after the first trimester. Because of that, they are avoided during pregnancy. Safer alternatives to manage maternal heart failure include hydralazine and nitrates, which lower afterload and preload, respectively, and can be used together to support the mother's circulation while minimizing fetal risk. This approach requires careful monitoring of the mother's blood pressure, kidney function, and fetal well-being, with therapy tailored to symptoms and tolerability. The other statements misstate fetal safety or teratogenic risk, so this option best reflects pregnancy considerations in heart failure management.

2. In acute HF treatment, which statement about vasodilatory therapy is listed?

A. Hospitalization

B. IV diuresis

C. Nesiritide recombinant human BNP

D. Nitrates and vasodilation

Vasodilators in acute heart failure work by lowering both preload and afterload, which unloads the failing heart, reduces pulmonary congestion, and can improve forward blood flow. Nitrates provide rapid venodilation, lowering LV filling pressures and, at higher doses, afterload as well. This quick reduction in filling pressures directly relieves dyspnea and pulmonary edema and is a central, practical approach when the patient's blood pressure can tolerate the drop. The other options aren't vasodilator therapies: hospitalization is a setting, IV diuresis targets fluid overload rather than vasodilation, and while nesiritide is a vasodilator, nitrates are the classic, commonly used vasodilator in acute decompensation.

3. What is the prognostic significance of LV remodeling measurements like LV dilation or LVESV?

A. EF is the only prognostic factor.

B. Greater LV dilation and higher LVESV are associated with worse prognosis; EF is also prognostic.

C. LV dilation signals better prognosis.

D. LVESV has no prognostic value.

Left ventricular remodeling is a key driver of prognosis in heart failure. When the ventricle dilates or the end-systolic volume (LVESV) increases, the heart works under greater stress, wall stress rises, and contractile efficiency tends to decline. These structural changes track disease severity and independently predict worse outcomes, including higher mortality and more hospitalizations. Ejection fraction (EF) remains a useful measure of systolic function, but it doesn't capture all the remodeling-related risk. So, greater LV dilation and higher LVESV point to a worse prognosis, and EF also has prognostic value. Choices claiming dilation signals better prognosis or that LVESV has no prognostic value misstate what remodeling measurements indicate.

4. Stage A risk factors for heart failure include all of the following except?

A. Prior congestive heart failure

B. Hypertension

C. Coronary artery disease

D. Diabetes mellitus

Stage A is about people at high risk for developing heart failure but who do not yet have structural heart disease or symptoms. Hypertension, coronary artery disease, and diabetes mellitus are conditions that increase HF risk and fit into Stage A because they can lead to heart failure if not treated. A history of congestive heart failure, on the other hand, shows that structural heart disease or current symptoms are already present, which moves a patient into a later stage. So prior congestive heart failure is not a Stage A risk factor, while the others are.

5. Which therapy provides both resynchronization and defibrillation capabilities?

A. Cardiac resynchronization therapy

B. Implantable cardioverter-defibrillator

C. Left ventricular assist device

D. Combined resynchronization therapy and defibrillator

Resynchronization therapy improves the timing of ventricular contractions, while defibrillation capability protects against life-threatening arrhythmias. The only option that provides both functions is the combined resynchronization therapy and defibrillator device, which integrates biventricular pacing to synchronize contraction with an implanted ICD that detects VT/VF and delivers shocks or pacing to terminate the arrhythmias. CRT alone doesn't shock, an ICD alone doesn't resynchronize, and a left ventricular assist device is a mechanical pump, not an electrical therapy. So the combined device is the correct choice.

6. Which statement correctly identifies HF type and EF range?

A. HFrEF: EF ≤40%

B. HFmrEF: EF ≥50%

C. HFpEF: EF 30-40%

D. HFimpEF: EF 60-70%

Understanding how heart failure is classified by ejection fraction helps clarify prognosis and treatment. Reduced EF means the heart's pumping ability is diminished, defined as an ejection fraction of 40% or less. There's an intermediate category with EF roughly 41–49%, and preserved EF is generally 50% or higher. HF with improved EF refers to patients who started with reduced EF and then had improvement, but it isn't defined by a fixed high range like 60–70%. The correct statement is that reduced EF corresponds to EF ≤40%. The other options misstate the standard ranges for the categories or describe an EF value not used to define HF with improved EF.

7. Which of the following is NOT listed as a risk factor for heart failure?

A. Coronary artery disease

B. Obesity

C. Hypertension

D. Diabetes

Risk factors for heart failure are conditions that either damage the heart muscle or increase the workload on the heart over time. Coronary artery disease is a direct cause of ischemic damage to the heart, making it a clear risk factor. Long-standing hypertension raises afterload, leading to left ventricular hypertrophy and eventual dysfunction. Diabetes is linked to both accelerated atherosclerosis and a form of diabetic cardiomyopathy, contributing to heart failure risk. Obesity is a major contributor to heart failure risk as well, but in some lists or question sets it may not be listed as a standalone risk factor. It often influences risk indirectly by promoting hypertension, insulin resistance, dyslipidemia, and increased cardiac workload, which then elevate HF risk. So, while obesity is clinically important for HF risk, the specific phrasing of this item reflects the list being used, where the other factors are named outright as risk factors and obesity is not listed in that set.

8. Which statement about SGLT2 inhibitors in heart failure is correct?

A. They are only used to treat diabetes with no cardiovascular benefit.

B. They only benefit HFrEF, not HFpEF.

C. They are contraindicated in HF due to hypotension risk.

D. They reduce hospitalization for heart failure and cardiovascular death across HFrEF and HFpEF.

SGLT2 inhibitors provide cardiovascular benefits in heart failure beyond glucose control. They reduce hospitalization for heart failure and cardiovascular death in patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). This has been shown in major trials such as DAPA-HF and EMPEROR-Reduced for HFrEF, and EMPEROR-Preserved and DELIVER for HFpEF, with benefits seen even in patients without diabetes. Mechanistically, they promote natriuresis and diuresis, improve renal hemodynamics, and may favorably affect myocardial energy use and remodeling, all contributing to better outcomes and symptoms. They are not contraindicated in heart failure due to hypotension risk; although they can cause volume depletion and lower blood pressure in some patients, the overall effect in heart failure is beneficial with appropriate monitoring. They are not limited to diabetes management with no cardiovascular benefit.

9. Why is BNP level interpretation age-dependent and what is a typical threshold for ruling out HF in non-elderly patients?

A. BNP thresholds are fixed and do not vary with age.

B. NT-proBNP thresholds vary with age; in younger patients a BNP <100 pg/mL or NT-proBNP <300 pg/mL helps rule out HF.

C. A BNP value below 200 pg/mL rules out HF in every patient.

D. BNP is not useful for ruling out HF in younger patients.

Natriuretic peptide levels rise with heart failure because the heart releases more in response to ventricular stretch, so they're useful to rule in or out HF. But these levels aren't the same in everyone; baseline amounts change with age, kidney function, obesity, and other factors. Because younger people tend to have lower baseline levels, using age-adjusted thresholds improves test performance. In non-elderly patients, a BNP below 100 pg/mL or NT-proBNP below 300 pg/mL has a high negative predictive value, meaning HF is unlikely if the symptom-driven testing is low at these thresholds. Higher thresholds are used in older patients because their baseline natriuretic peptide levels tend to be higher even without HF. So the age-dependent interpretation helps avoid missing HF in older individuals while not overcalling it in younger patients.

10. Which medication class is identified as warranting potassium monitoring when added to RAAS inhibitors in heart failure?

A. Potassium-sparing diuretics

B. Beta-blockers

C. ACE inhibitors

D. Calcium channel blockers

Potassium-sparing diuretics are the class that necessitates potassium monitoring when added to RAAS inhibitors in heart failure. These drugs prevent potassium loss in the distal nephron or block aldosterone itself, leading to higher potassium levels. RAAS inhibitors already raise potassium by reducing aldosterone-driven potassium excretion, so combining them with potassium-sparing agents markedly increases the risk of hyperkalemia. Checking potassium (and renal function) after starting or adjusting therapy helps prevent dangerous elevations. Other options don't have this specific additive effect on potassium. Beta-blockers don't directly affect potassium balance in this context, and calcium channel blockers don't significantly raise potassium. ACE inhibitors are RAAS inhibitors themselves, and while potassium monitoring is important with them, the scenario described points to the potassium-sparing diuretics as the class that most clearly requires close potassium surveillance when used with RAAS inhibitors.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://congestiveheartfailure.examzify.com

We wish you the very best on your exam journey. You've got this!